

# Cybin Expands to Europe and Provides Update on Intellectual Property Portfolio

7.8.21

TORONTO,  
CANADA

–

July

8,

2021

–

[Cybin](#)

[Inc.](#)

[\(NEO:CYBN\)](#)



[Our Work](#)

[Investors](#)

[About Us](#)

or

the  
“Company”),  
a  
biotechnology  
company  
focused  
on  
progressing  
psychedelic  
therapeutics,  
today  
announced  
the  
scaling  
up  
of  
its  
European  
operations  
and  
research  
activities  
with  
various



[Our Work](#)

[Investors](#)

[About Us](#)

clinical

research  
organizations,  
including  
the  
transfer  
of  
its  
intellectual  
property  
assets  
to  
its  
recently  
formed  
wholly-  
owned  
Ireland  
subsidiary.

The  
Company  
continues  
its  
progression  
of



[Our Work](#)

[Investors](#)

[About Us](#)

building  
upon  
its  
IP  
portfolio  
of  
novel  
psychedelic  
compounds,  
delivery  
platforms  
and  
methods  
of  
use  
in  
psychiatric  
indications.

Since  
inception,  
the  
Company  
has



[Our Work](#)

[Investors](#)

[About Us](#)

to  
progress  
the  
following  
initiatives  
all  
of  
which  
are  
accelerated  
from  
its  
growing  
portfolio  
of  
intellectual  
property:

-



[Our Work](#)

[Investors](#)

[About Us](#)



[Our Work](#)

[Investors](#)

[About Us](#)



[Our Work](#)

[Investors](#)

[About Us](#)





Cybin  
is  
a  
leading  
biotechnology  
company  
focused  
on  
progressing  
psychedelic  
therapeutics  
by  
utilizing  
proprietary  
drug  
discovery  
platforms,  
innovative  
drug  
delivery  
systems,  
novel  
formulation  
approaches



[Our Work](#)

[Investors](#)

[About Us](#)

regimens

for  
psychiatric  
disorders.

**Cautionary  
Notes  
and  
Forward-  
Looking  
Statements**

Certain  
statements  
in  
this  
news  
release  
related  
to  
the  
Company  
are  
forward-  
looking



[Our Work](#)

[Investors](#)

[About Us](#)

are

prospective

in

nature.

Forward-

looking

statements

are

not

based

on

historical

facts,

but

rather

on

current

expectations

and

projections

about

future

events

and

are



[Our Work](#)

[Investors](#)

[About Us](#)

to

risks  
and  
uncertainties  
which  
could  
cause  
actual  
results  
to  
differ  
materially  
from  
the  
future  
results  
expressed  
or  
implied  
by  
the  
forward-  
looking  
statements.

These



[Our Work](#)

[Investors](#)

[About Us](#)

can

be  
identified  
by  
the  
use  
of  
forward-  
looking  
words  
such  
as  
“may”,  
“should”,  
“could”,  
“intend”,  
“estimate”,  
“plan”,  
“anticipate”,  
“expect”,  
“believe”  
or  
“continue”,  
or  
the



[Our Work](#)

[Investors](#)

[About Us](#)

or

similar variations. Forward-looking statements in this news release include statements regarding the Company scaling and building upon its IP portfolio, progression in relation



[Our Work](#)

[Investors](#)

[About Us](#)

Company's

four  
active  
drug  
programs,  
and  
the  
potential  
for  
the  
Company  
to  
obtain  
patent  
coverage  
in  
153  
countries.  
There  
are  
numerous  
risks  
and  
uncertainties  
that



[Our Work](#)

[Investors](#)

[About Us](#)

actual

results  
and  
Cybin's  
plans  
and  
objectives  
to  
differ  
materially  
from  
those  
expressed  
in  
the  
forward-  
looking  
information.

Actual  
results  
and  
future  
events  
could  
differ



[Our Work](#)

[Investors](#)

[About Us](#)

those



anticipated

in

such

information.

These

and

all

subsequent

written

and

oral

forward-

looking

information

are

based

on

estimates

and

opinions

of

management

on

the



[Our Work](#)

[Investors](#)

[About Us](#)

are

made  
and  
are  
expressly  
qualified  
in  
their  
entirety  
by  
this  
notice.  
Except  
as  
required  
by  
law,  
the  
Company  
does  
not  
intend  
to  
update  
these



[Our Work](#)

[Investors](#)

[About Us](#)

statements.

Cybin

Cybin

makes

no

medical,

treatment

or

health

benefit

claims

about

Cybin's

proposed

products.

The

U.S.

Food

and

Drug

Administration,

Health

Canada

or

other

similar



[Our Work](#)

[Investors](#)

[About Us](#)

have

not  
evaluated  
claims  
regarding  
psilocybin,  
psychedelic  
tryptamine,  
tryptamine  
derivatives  
or  
other  
psychedelic  
compounds  
or  
nutraceutical  
products.  
The  
efficacy  
of  
such  
products  
have  
not  
been



[Our Work](#)

[Investors](#)

[About Us](#)

approved

research.

There

is

no

assurance

that

the

use

of

psilocybin,

psychedelic

tryptamine,

tryptamine

derivatives

or

other

psychedelic

compounds

or

nutraceuticals

can

diagnose,

treat,

cure



[Our Work](#)

[Investors](#)

[About Us](#)

any

Cybin

disease  
or  
condition.  
Vigorous  
scientific  
research  
and  
clinical  
trials  
are  
needed.  
Cybin  
has  
not  
conducted  
clinical  
trials  
for  
the  
use  
of  
its  
proposed  
products.



[Our Work](#)

[Investors](#)

[About Us](#)

to

quality,  
consistency,  
efficacy  
and  
safety  
of  
potential  
products  
do  
not  
imply  
that  
Cybin  
verified  
such  
in  
clinical  
trials  
or  
that  
Cybin  
will  
complete  
such



[Our Work](#)

[Investors](#)

[About Us](#)

Cybin

cannot  
obtain  
the  
approvals  
or  
research  
necessary  
to  
commercialize  
its  
business,  
it  
may  
have  
a  
material  
adverse  
effect  
on  
Cybin's  
performance  
and  
operations.



[Our Work](#)

[Investors](#)

[About Us](#)



*Exchange*

*has*

*neither*

*approved*

*nor*

*disapproved*

*the*

*contents*

*of*

*this*

*news*

*release*

*and*

*is*

*not*

*responsible*

*for*

*the*

*adequacy*

*and*

*accuracy*

*of*

*the*

*contents*



[Our Work](#)

[Investors](#)

[About Us](#)

## Investor

### Contacts:

Tim

Regan/Scott

Eckstein

KCSA

Strategic

Communications

[Cybin@kcsa.com](mailto:Cybin@kcsa.com)

Lisa

M.

Wilson

In-

Site

Communications,

Inc.

[lwilson@insitecony.com](mailto:lwilson@insitecony.com)

## Media

### Contacts:

· ·



[Our Work](#)

[Investors](#)

[About Us](#)

PREVIOUS POST

NEXT POST



5600-100 King St W, Toronto ON

M5X 1C9

Investor Contact: [ir@cybin.com](mailto:ir@cybin.com)

General Contact:

[info@cybin.com](mailto:info@cybin.com)

### Our Work

[Development Pipeline](#)

[The Science](#)

[Cybin x Kernel](#)

### Investors

[Press Releases](#)

[Financials](#)

[Corporate Governance](#)

[Downloads](#)

### About Us

[Mission](#)

[Team](#)

[News](#)

[Join Us](#)

[Contact](#)



[Our Work](#)

[Investors](#)

[About Us](#)

